Dr. Marion Jung was formerly Principal of Earlybird.
More than 13 years experience as investor; focus on medical technology, pharmaceutical industry, cleantech Serves as reviewer for KMU-innovativ grants, provided by the Federal Ministry of Education and Research for SME companies
Shared responsibility for Amaxa (to Lonza, SWX: LONN), Wilex (IPO Prime Standard FSE: WL6), Dianoema (IPO Milan: NOE.MI)
Postdoctorate at Chair for Molecular Biology, Ludwig Maximilian University, Munich Research at Arizona State University and Marine Biological Laboratory, Massachusetts Dipl.-Biol. (MS equivalent) and PhD, Ludwig Maximilian University, Munich
